Table 6.
Absorption rate of topotecan (2 mg/kg) at 30 min after its oral administration with or without P-gp inhibitor in WT, mdr1a/1b KO and bcrp KO mice.
| n | +Inhibitor (mg/kg) |
Cpv (nM) | Csys (nM) | Cpv − Csys (nM) | Absorption Rate V (nmol/min/kg) |
|
|---|---|---|---|---|---|---|
| WT mice | 3 | 196 ± 29 | 179 ± 25 | 17.1 ± 5.7 | 1.29 | |
| +Cyclosporin A | 2 | 30 | 298 | 240 | 58.5 | 4.40 |
| +LY335979 | 3 | 30 | 249 ± 26 | 228 ± 22.3 | 20.5 ± 9.7 | 1.54 |
| +WK-X-34 | 3 | 30 | 464 ± 53 | 388 ± 19 | 76.6 ± 27 | 5.76 |
| mdr1a/1b KO mice | 3 | 236 ± 30 | 207 ± 28 | 28.9 ± 8.4 | 2.17 | |
| bcrp KO mice | 3 | 469 ± 64 | 398 ± 88 | 70.5 ± 20 | 5.30 |
Data are represented as mean ± S.D. bcrp: breast cancer resistance protein.